1. Recognize the evidence on the efficacy and tolerability of ADHD medications based on randomized
2. Identify the evidence on the effectiveness and safety of ADHD medications based on observational
3. Evaluate the issue in relation to the assessment of the effect of ADHD in the long term.
Dr Cortese will provide an overview of the evidence on the efficacy and tolerability of ADHD medications from randomized controlled trials as well as of the effectiveness and safety of ADHD medications from observational studies, in particular from within individual studies.
In terms of outcomes, he will focus on core ADHD symptoms as well as other outcomes (eg, physical injuries, car accidents, suicidal ideation.
He will also address the evidence on long term effect of ADHD based on findings from discontinuation RCTs.
Samuele Cortese, MD, PhD is currently Full Professor of Child and Adolescent Psychiatry at the University of Southampton and Honorary Consultant Child and Adolescent Psychiatry for Solent NHS Trust. He is also Adjunct Full Professor with the New York University (NYU).
Prof. Cortese’s main research interest are around neurodevelopmental disorders, with a focus on ADHD. In his research, he uses advanced evidence synthesis methods to address clinically relevant questions. He has published more than 250 peer-review papers, including first author papers in prestigious journals such as the New England Journal of Medicine, The Lancet Psychiatry and the American Journal of Psychiatry. He is Deputy Editor for the Journal of the American Academy of Child and Adolescent Psychiatry and sits on the editorial board of other 5 international journals. He is a member of the European ADHD Guidelines Group, as well as of the child and adolescent psychiatry faculty of the European Collegium of Neuropsychopharmacology and of the British Association of Psychopharmacology-child and adolescent psychiatry module. In 2020, Prof. Cortese was included in the list of the world’s most influential researchers of the past decade, demonstrated by the production of multiple highly-cited papers that rank in the top 1% by citations in the field of psychiatry/psychology in 2019 in Web of Science. In 2022, he ranked #1 worldwide in terms of expertise on Attention Deficit Hyperactivity Disorder (ADHD) according to Expertscape .
CADDRA – Canadian ADHD Resource Alliance has been approved by the College of Family Physicians, the Royal College of Physicians and Surgeons of Canada and the Canadian Psychological Association to offer 1 continuing education credits for this session. CADDRA maintains responsibility for the program. Participation in a discussion forum and completion of a reflective exercise are required for certification.